<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00750971</url>
  </required_header>
  <id_info>
    <org_study_id>CT-1306</org_study_id>
    <nct_id>NCT00750971</nct_id>
  </id_info>
  <brief_title>Autologous Stem Cell Transplantation for Refractory Systemic Lupus Erythematosus (ASSIST)</brief_title>
  <acronym>ASSIST</acronym>
  <official_title>An Open-Label, Phase II Multicenter Cohort Study of Immunoablation With Cyclophosphamide and Antithymocyte-Globulin and Transplantation of Autologous Cd34-Enriched Hemapoietic Stem Cells Versus Currently Available Immunosuppressive/Immunomodulatory Therapy for Treatment of Refractory Systemic Lupus Erythematosus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Charite University, Berlin, Germany</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Charite University, Berlin, Germany</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      While glucocorticoids and immunosuppressants ameliorate manifestations of SLE in many
      patients, current therapies are insufficient to control the disease in a subset of patients,
      and their clinical prognosis remains poor due to the development of vital organ failure,
      cumulative drug toxicity and to the increased risk of cardiovascular disease and malignancy.
      Immunoablative chemotherapy followed by autologous hematopoietic stem cell transplantation
      (ASCT) has recently emerged as a promising experimental therapy for severely affected
      patients, providing them the potential to achieve treatment-free, long-term remission. The
      investigators postulate that immunoablative therapy eliminates or effectively reduces the
      level of autoreactive T and B lymphocytes and then regeneration of de novo immunity resets
      the autoreactive immune system into a self-tolerant, protective immune system resulting in
      prolonged and treatment-free remission.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>August 2008</start_date>
  <completion_date type="Anticipated">August 2020</completion_date>
  <primary_completion_date type="Anticipated">July 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>SLEDAI</measure>
    <time_frame>48 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Serologic response (autoantibodies)</measure>
    <time_frame>48 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immune Reconstitution</measure>
    <time_frame>48 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Organ-specific response parameters</measure>
    <time_frame>48 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Systemic Lupus Erythematosus</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Immunoablation and Autologous Hematopoietic Stem Cell Transplantation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Best currently available immunosuppressive/immunomodulatory therapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Immunoablation and Autologous Hematopoietic Stem Cell Transplantation</intervention_name>
    <description>Transplantation of purified CD34+ autologous hematopoietic stem cells mobilized with cyclophosphamide (200mg/m2)and G-CSF (10µg/kg/d) after immunoablation with cyclophosphamide (200mg/kg)and rabbit-antithymocyteglobulin (90mg/kg)</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Diagnosis of SLE according to American College of Rheumatology (ACR) classification
             criteria

          2. Age between 18 and 60 years, inclusive

          3. Provision of informed consent

          4. Active disease, refractory to standard immunosuppressive therapy defined as:

               -  BILAG level A and a SLEDAI-score of at least 10, despite treatment with high-dose
                  corticosteroids and pulse intravenous CYC at doses of 500-1000mg/m2 for at least
                  6 months or mycophenolate mofetil (MMF) at doses of at least 2g -

               -  Lupus nephritis with renal biopsy performed within one year prior to screening
                  showing glomerulonephritis WHO class III or IV

               -  Parenchymal disease of heart or lung

               -  Neuropsychiatric lupus

               -  Autoimmune cytopenia OR

               -  recurrence of disease activity (defined as BILAG level A and a SLEDAI of at least
                  10) within one year after successful induction therapy with cyclophosphamide or
                  MMF in the presence of an adequate maintenance therapy with either
                  cyclophosphamide (at least 500mg/m2 monthly), mycophenolate mofetil (at least 2g
                  daily), azathioprine (at least 1.5mg/kg/d), methotrexate (at least 15mg weekly),
                  cyclosporine (at least 3mg/kg/d) in patients with persistent anti-dsDNA
                  antibodies

        Exclusion Criteria:

          1. Severe concomitant disease or organ damage

               -  renal: renal insufficiency with glomerular filtration rate below 40ml/min

               -  cardiac: congestive heart failure, LVEF &lt; 40% determined by echocardiogram,
                  uncontrolled arrhythmia

               -  pulmonary: mean pulmonary arterial pressure &gt;50mmHg, DLCO &lt; 40 % predicted

               -  gastrointestinal: liver cirrhosis; SGOT, SGPT greater than 2 x the upper limit of
                  normal, unless due to active lupus

          2. Ongoing cancer or history of malignancy within 5 years of screening

          3. Women who are pregnant or breastfeeding or use non-reliable methods of contraception

          4. Subjects with active systemic infection

          5. Subjects with history of active viral infection within 6 months prior to screening,
             known HIV-infection or chronic Hepatitis B or Hepatitis C

          6. History of allergic reaction to cyclophosphamide, G-CSF or ATG

          7. Use of immunosuppressive agents for indications other than SLE

          8. Any comorbidity that in the opinion of the investigator would jeopardize the ability
             of the subject to tolerate therapy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Falk Hiepe, Prof</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universitätsmedizin Charité</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Falk Hiepe, Prof.</last_name>
    <phone>+49 30 450 513026</phone>
    <email>falk.hiepe@charite.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Renate Arnold, Prof.</last_name>
    <phone>+49 30 450-553-302</phone>
    <email>renate.arnold@charite.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Universitätsmedizin Charité</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Falk Hiepe, Prof</last_name>
      <phone>+49 30 450 513026</phone>
    </contact>
    <investigator>
      <last_name>Falk Hiepe, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinik Düsseldorf</name>
      <address>
        <city>Düsseldorf</city>
        <zip>40225</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mathias Schneider, Prof.</last_name>
      <phone>+49 (0) 211-8117817</phone>
    </contact>
    <investigator>
      <last_name>Mathias Schneider, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Essen</name>
      <address>
        <city>Essen</city>
        <zip>45239 Essen</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christoph Specker, Prof.</last_name>
      <phone>+49 (0)201-84081214</phone>
    </contact>
    <investigator>
      <last_name>Christoph Specker, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinik Heidelberg</name>
      <address>
        <city>Heidelberg</city>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hanns-Marting Lorenz, Prof.</last_name>
      <phone>+49 (0) 6221-568044</phone>
    </contact>
    <investigator>
      <last_name>Hanns-Martin Lorenz, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinik Köln</name>
      <address>
        <city>Köln</city>
        <zip>50937</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrea Rubbert-Roth, PD</last_name>
      <phone>+49 (0) 221-4783993</phone>
    </contact>
    <investigator>
      <last_name>Andrea Rubbert-Roth, PD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitäsklinik Mainz</name>
      <address>
        <city>Mainz</city>
        <zip>55101</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karin Kolbe, MD</last_name>
    </contact>
    <investigator>
      <last_name>Karin Kolbe, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinik Tübingen</name>
      <address>
        <city>Tübingen</city>
        <zip>72026</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ina Kötter, PD</last_name>
      <phone>+49 (0) 7071-2984095</phone>
    </contact>
    <investigator>
      <last_name>Ina Kötter, PD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinik Würzburg</name>
      <address>
        <city>Würzburg</city>
        <zip>97070</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hans-Peter Tony, Prof.</last_name>
      <phone>+49 (0) 931-20170420</phone>
    </contact>
    <investigator>
      <last_name>Hans-Peter Tony, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <reference>
    <citation>Thiel A, Alexander T, Schmidt CA, Przybylski GK, Kimmig S, Kohler S, Radtke H, Gromnica-Ihle E, Massenkeil G, Radbruch A, Arnold R, Hiepe F. Direct assessment of thymic reactivation after autologous stem cell transplantation. Acta Haematol. 2008;119(1):22-7. doi: 10.1159/000117824. Epub 2008 Feb 22.</citation>
    <PMID>18292651</PMID>
  </reference>
  <reference>
    <citation>Jayne D, Passweg J, Marmont A, Farge D, Zhao X, Arnold R, Hiepe F, Lisukov I, Musso M, Ou-Yang J, Marsh J, Wulffraat N, Besalduch J, Bingham SJ, Emery P, Brune M, Fassas A, Faulkner L, Ferster A, Fiehn C, Fouillard L, Geromin A, Greinix H, Rabusin M, Saccardi R, Schneider P, Zintl F, Gratwohl A, Tyndall A; European Group for Blood and Marrow Transplantation; European League Against Rheumatism Registry. Autologous stem cell transplantation for systemic lupus erythematosus. Lupus. 2004;13(3):168-76.</citation>
    <PMID>15119545</PMID>
  </reference>
  <reference>
    <citation>Rosen O, Thiel A, Massenkeil G, Hiepe F, Häupl T, Radtke H, Burmester GR, Gromnica-Ihle E, Radbruch A, Arnold R. Autologous stem-cell transplantation in refractory autoimmune diseases after in vivo immunoablation and ex vivo depletion of mononuclear cells. Arthritis Res. 2000;2(4):327-36. Epub 2000 Jun 8.</citation>
    <PMID>11056673</PMID>
  </reference>
  <reference>
    <citation>Alexander T, Thiel A, Rosen O, Massenkeil G, Sattler A, Kohler S, Mei H, Radtke H, Gromnica-Ihle E, Burmester GR, Arnold R, Radbruch A, Hiepe F. Depletion of autoreactive immunologic memory followed by autologous hematopoietic stem cell transplantation in patients with refractory SLE induces long-term remission through de novo generation of a juvenile and tolerant immune system. Blood. 2009 Jan 1;113(1):214-23. doi: 10.1182/blood-2008-07-168286. Epub 2008 Sep 29.</citation>
    <PMID>18824594</PMID>
  </reference>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 10, 2008</study_first_submitted>
  <study_first_submitted_qc>September 10, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 11, 2008</study_first_posted>
  <last_update_submitted>March 17, 2017</last_update_submitted>
  <last_update_submitted_qc>March 17, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 20, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Charite University, Berlin, Germany</investigator_affiliation>
    <investigator_full_name>Falk Hiepe</investigator_full_name>
    <investigator_title>Prof. Dr. Falk Hiepe</investigator_title>
  </responsible_party>
  <keyword>ASSIST</keyword>
  <keyword>SLE</keyword>
  <keyword>Stem Cell Transplantation</keyword>
  <keyword>Tolerance</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lupus Erythematosus, Systemic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Immunosuppressive Agents</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

